# China NMPA Drug Inspection - Jilin Wantong Pharmaceutical Group Meihe Pharmaceutical Co., Ltd. - Gynecological Menstrual Regulating Tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/jilin-wantong-pharmaceutical-group-meihe-pharmaceutical-co-ltd/02b2db42-635c-4160-90fe-62088135343c/
Source feed: China

> China NMPA drug inspection for Jilin Wantong Pharmaceutical Group Meihe Pharmaceutical Co., Ltd. published January 05, 2018. Drug: Gynecological Menstrual Regulating Tablets. The National Medical Products Administration (NMPA) of China issued Announcement No. 5 of 2018 on January 5, 2018, repor

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 5 of 2018 from the State Administration for Market Regulation regarding 20 batches of substandard drugs.
- Company Name: Jilin Wantong Pharmaceutical Group Meihe Pharmaceutical Co., Ltd.
- Publication Date: 2018-01-05
- Drug Name: Gynecological Menstrual Regulating Tablets
- Inspection Finding: [Inspection] (Weight Difference)
- Action Taken: Relevant provincial-level food and drug administration departments have taken control measures such as sealing and seizing goods, requiring enterprises to suspend sales and use, recall products, and rectify the situation. The State Food and Drug Administration has instructed the provincial-level food and drug administration departments where the relevant entities are located to investigate the illegal activities of the aforementioned enterprises in producing and selling substandard drugs in accordance with Articles 73, 74, and 75 of the "Drug Administration Law of the People's Republic of China," and to publicly disclose the results of the handling of the relevant enterprises or entities within three months, and to promptly report the relevant information to the State Food and Drug Administration.
- Summary: The National Medical Products Administration (NMPA) of China issued Announcement No. 5 of 2018 on January 5, 2018, reporting 20 batches of substandard drugs from 12 manufacturers. The findings stemmed from testing conducted by five drug testing institutions, including the Guizhou Provincial Institute for Food and Drug Control. Key companies identified include Jiangxi Yongsheng Biochemical Pharmaceutical Co., Ltd., Wuhan Kangle Pharmaceutical Co., Ltd., Chengdu Zhengkang Pharmaceutical Co., Ltd., Diaoyutai Pharmaceutical Group Jilin Tianqi Pharmaceutical Co., Ltd., and Jilin Wantong Pharmaceutical Group Meihe Pharmaceutical Co., Ltd., among others. The substandard products encompassed various pharmaceutical forms, such as oral solutions, capsules, and tablets. The primary issues discovered included critical quality deviations such as incorrect fill volume, insufficient or incorrect content determination (e.g., active ingredients like camphor or toad venom), excessive moisture content, non-compliance with microbial limits, and unacceptable weight variation in tablets. In response, provincial food and drug administrations implemented immediate control measures, including sealing and seizing affected products, mandating sales suspension, product recalls, and requiring manufacturers to rectify the identified problems. Furthermore, the NMPA directed provincial authorities to investigate these illegal activities in accordance with Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*. The results of these investigations and the subsequent handling of the enterprises must be publicly disclosed within three months, with reports submitted to the NMPA.

Company: https://www.globalkeysolutions.net/companies/jilin-wantong-pharmaceutical-group-meihe-pharmaceutical-co-ltd/72508d62-c7ca-4603-9b30-b5c5f80c2794/